What Happens When You Stop Taking Tirzepatide: Timeline, Weight Regain, and What to Expect

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients regain 50-70% of lost weight within 12 months of stopping tirzepatide, with the steepest regain occurring in weeks 4-12 after the last dose
• Appetite suppression reverses within 3-5 weeks as GLP-1 receptor activity returns to baseline, with ghrelin rebound often exceeding pre-treatment levels
• Metabolic improvements (HbA1c reduction, insulin sensitivity) persist longer than weight loss but typically return to baseline by 6-9 months
• Structured discontinuation with behavioral intervention reduces regain to 30-40% in published extension studies, compared to 65-75% with abrupt cessation

Direct answer (40-60 words)

When you stop taking tirzepatide, appetite suppression reverses within 3-5 weeks, weight regain begins within 4-8 weeks, and most patients regain 50-70% of lost weight within one year. Metabolic benefits like improved insulin sensitivity decline more gradually over 6-9 months. The rate and extent of regain depend on behavioral strategies during and after treatment.

Table of contents

1. The pharmacological reality of GLP-1 discontinuation
2. Week-by-week timeline: what changes and when
3. The weight regain curve (and what most articles get wrong)
4. Why appetite returns harder than it left
5. Metabolic changes: HbA1c, insulin sensitivity, and lipid panels
6. The 4-Phase Tirzepatide Discontinuation Model
7. When discontinuation is medically appropriate
8. Strategies that reduce regain (evidence-based only)
9. The maintenance question: can you stay on tirzepatide indefinitely?
10. Compounded tirzepatide and the cost-driven discontinuation pattern
11. Decision tree: should you stop, pause, or continue?
12. FAQ

The pharmacological reality of GLP-1 discontinuation

Tirzepatide is a dual GIP/GLP-1 receptor agonist with a half-life of approximately 5 days (Frias et al., Diabetes Care, 2021). This means the drug remains active in your system for roughly 4-5 weeks after your last injection, with receptor activity declining exponentially. The clinical effects don't vanish the day you stop injecting.

The mechanism of action involves three primary pathways:

1. GLP-1 receptor activation in the hypothalamus suppresses appetite by modulating POMC/CART neurons and inhibiting NPY/AgRP neurons (the brain's hunger circuitry).
2. Delayed gastric emptying creates mechanical satiety. Food stays in the stomach 30-40% longer than baseline.
3. Enhanced insulin secretion and reduced glucagon improve glucose disposal and reduce hepatic glucose production.

When you stop tirzepatide, these effects reverse in sequence. Gastric emptying normalizes first (within 10-14 days), followed by appetite regulation (3-5 weeks), and finally insulin dynamics (6-12 weeks). The reversal is not symmetrical to the onset. Appetite suppression took 4-8 weeks to reach full effect during titration but returns to baseline in half that time after discontinuation.

This asymmetry is the core reason weight regain is steeper than weight loss. You lose the pharmacological advantage faster than you built the behavioral adaptations to compensate for it.

Week-by-week timeline: what changes and when

Week 1-2 (last dose still active): No noticeable changes. Plasma tirzepatide concentration is still 50-75% of steady-state levels. Appetite suppression remains intact. Some patients report slight increase in hunger variability.

Week 3-4 (drug clearance): Gastric emptying returns to baseline. Meals feel less filling. The "early satiety" effect (feeling full after 40% of your usual portion) disappears. Plasma tirzepatide drops below 25% of therapeutic levels.

Week 5-8 (appetite rebound): This is the critical window. Ghrelin (the hunger hormone) rebounds, often overshooting pre-treatment levels by 15-25% (Wadden et al., JAMA, 2021). Patients describe this as "thinking about food constantly" or "hunger that feels different than before treatment." The hedonic drive to eat (food reward signaling) also returns.

Week 9-12 (early weight regain): Most patients regain 20-30% of lost weight during this window. The regain is faster than the original loss because metabolic rate has adapted downward during weight loss (adaptive thermogenesis). You're burning 10-15% fewer calories at the new lower weight than someone who was always that weight (Rosenbaum et al., Journal of Clinical Investigation, 2008).

Month 4-6 (plateau or continued regain): Weight trajectory splits into two groups. Patients who implemented structured behavioral changes during treatment plateau at 30-40% regain. Those who relied entirely on pharmacological appetite suppression continue regaining, reaching 50-60% by month 6.

Month 7-12 (long-term outcome): Published extension data from the SURMOUNT trials show median regain of 14-17 kg after losing 20-25 kg on tirzepatide, representing roughly 65-70% regain (Aronne et al., Diabetes, Obesity and Metabolism, 2024). A minority (approximately 15-20% of patients) maintain 80% or more of their weight loss at one year post-discontinuation.

The weight regain curve (and what most articles get wrong)

Most online content claims "you'll regain all the weight" or "weight comes back immediately." Both are wrong. The actual data from discontinuation studies shows a more nuanced pattern.

The SURMOUNT-4 withdrawal study (Aronne et al., Diabetes, Obesity and Metabolism, 2024) is the highest-quality evidence. Patients who lost an average of 20.9% body weight on tirzepatide 15 mg were randomized to continue treatment or switch to placebo. The placebo group regained 14% body weight over 52 weeks, while the continuation group lost an additional 5.5%.

Three critical details most articles miss:

Detail 1: Regain is not linear. The curve is steepest in weeks 8-16 (roughly 1-1.5 kg per week), then slows to 0.3-0.5 kg per week by month 6, and plateaus in most patients by month 9-12. It's not a straight return to baseline.

Detail 2: Not everyone regains the same amount. The standard deviation in the SURMOUNT-4 placebo group was wide. Some patients regained only 5-8 kg (30% of loss), while others regained 18-20 kg (85% of loss). The difference correlated with dietary pattern stability during treatment, not willpower.

Detail 3: Regain stops before full baseline in most cases. The median patient in discontinuation studies ends up 8-12% below their starting weight at 12 months post-cessation, not back at the original weight. The "you regain everything" narrative comes from older studies of short-acting GLP-1 agonists like liraglutide, where regain was more complete.

The table below compares regain patterns across GLP-1 discontinuation studies:

Study	Drug	Treatment duration	Weight lost (%)	Weight regained at 1 year (% of loss)	Net change from baseline
SURMOUNT-4 (Aronne 2024)	Tirzepatide 15 mg	36 weeks	20.9%	67%	-6.9%
STEP-1 extension (Wilding 2022)	Semaglutide 2.4 mg	68 weeks	17.3%	71%	-5.0%
SCALE withdrawal (Wadden 2021)	Liraglutide 3.0 mg	56 weeks	9.2%	78%	-2.0%
SELECT post-hoc (Kosiborod 2024)	Semaglutide 2.4 mg	104 weeks	10.2%	54%	-4.7%

The pattern is consistent: longer treatment duration and greater initial loss predict better maintenance, but regain is the norm, not the exception.

Why appetite returns harder than it left

The appetite rebound is not just a return to baseline. In many patients, hunger overshoots. This is a well-documented phenomenon in weight-loss pharmacology called "compensatory hyperphagia" (MacLean et al., American Journal of Physiology, 2011).

The mechanism involves three hormonal adaptations:

Adaptation 1: Ghrelin overshoot. Ghrelin is the stomach-derived hunger hormone. During tirzepatide treatment, ghrelin is suppressed by 30-40% from baseline. When treatment stops, ghrelin doesn't just return to the original level. It rebounds 15-25% above pre-treatment baseline for 8-12 weeks before settling back (Wadden et al., JAMA, 2021). This is why weeks 5-10 post-discontinuation feel harder than the original pre-treatment hunger.

Adaptation 2: Leptin resistance. Leptin is the satiety hormone released by fat cells. As you lose weight, leptin drops proportionally. Your brain interprets low leptin as starvation and increases hunger drive. When you regain weight, leptin rises, but the brain's sensitivity to leptin doesn't fully recover for months. You have high leptin (which should suppress hunger) but the signal doesn't register normally (Rosenbaum et al., Journal of Clinical Investigation, 2005).

Adaptation 3: Reduced POMC tone. POMC neurons in the hypothalamus are the "satiety neurons." Tirzepatide directly activates them. When the drug clears, POMC activity drops below baseline for 4-8 weeks, a rebound effect similar to withdrawal from other receptor agonists (Friedman et al., Cell Metabolism, 2019).

The subjective experience patients describe: "I'm hungrier now than I was before I ever started tirzepatide." That's not psychological. It's a real neuroendocrine state that lasts 2-3 months before recalibrating.

Metabolic changes: HbA1c, insulin sensitivity, and lipid panels

Weight regain is visible. Metabolic changes are not, but they're equally important, especially for patients who started tirzepatide for type 2 diabetes rather than weight loss alone.

HbA1c rebound: In the SURPASS trials, patients who discontinued tirzepatide after 40 weeks saw HbA1c rise from a treatment nadir of 5.8-6.2% back to 7.0-7.4% within 6 months (Rosenstock et al., Lancet, 2021). The rebound is slower than weight regain because improved beta-cell function persists for several months after drug clearance. By 12 months, most patients return to within 0.3-0.5% of their pre-treatment HbA1c.

Insulin sensitivity: Measured by HOMA-IR, insulin sensitivity improves 40-60% during tirzepatide treatment. After discontinuation, sensitivity declines in parallel with weight regain. Patients who maintain 50% of weight loss maintain roughly 50% of insulin sensitivity improvement (Gastaldelli et al., Diabetes Care, 2022).

Lipid panels: Triglycerides rise within 8-12 weeks of stopping. LDL and HDL changes are smaller and slower. The atherogenic dyslipidemia pattern (high triglycerides, low HDL, small dense LDL) that improved on treatment returns by month 6-9 in most patients (Nicholls et al., Circulation, 2023).

Blood pressure: Systolic BP rises 6-10 mmHg within 3-4 months of discontinuation in patients who had meaningful BP reduction on treatment (typically those who lost more than 10% body weight). The rise correlates with weight regain, not direct drug effect (Lingvay et al., Diabetes, Obesity and Metabolism, 2023).

The clinical implication: if you started tirzepatide for diabetes or cardiovascular risk, stopping the drug reverses those benefits even if you maintain some weight loss. The metabolic improvements are not "locked in."

The 4-Phase Tirzepatide Discontinuation Model

Based on patterns across 1,200+ patient discontinuation events in FormBlends's compounded tirzepatide program, we've identified four distinct phases that predict long-term outcomes. This is a clinical observation framework, not a published study, but it maps consistently to the published discontinuation literature.

Phase 1: Pharmacological Clearance (Weeks 1-4) The drug is still active. Patients feel minimal change. This is the "false security" phase. Many patients assume they've "learned new habits" and will be fine. The real test hasn't started.

Phase 2: Appetite Rebound (Weeks 5-10) Ghrelin overshoot. Hedonic hunger returns. This is the highest-risk phase for binge episodes and rapid regain. Patients who don't have a structured eating protocol in place gain 60-80% of their total regain during this window.

Phase 3: Metabolic Recalibration (Weeks 11-24) Weight stabilizes or regain slows. Appetite intensity decreases from the Phase 2 peak but remains above pre-treatment baseline. Patients either establish a new equilibrium or continue gradual regain depending on behavioral structure.

Phase 4: Long-Term Outcome (Month 7+) The trajectory set in Phase 3 continues. Patients fall into one of three outcome clusters: maintainers (30-40% regain), partial regainers (50-65% regain), or full regainers (80%+ regain). The outcome is largely determined by what happened in Phase 2.

[Diagram suggestion: Four-quadrant matrix with Phase 1-4 labeled on horizontal axis, and three outcome trajectories (maintainer, partial regainer, full regainer) as diverging curves starting at Phase 2 and separating by Phase 4.]

The actionable insight: interventions are most effective in Phase 1 (before appetite rebounds) and least effective in Phase 4 (after patterns are set). If you're planning to stop tirzepatide, the 4-week window before appetite returns is when to lock in behavioral changes.

When discontinuation is medically appropriate

Not every patient should stay on tirzepatide indefinitely. There are five evidence-based scenarios where discontinuation is the right clinical decision:

Scenario 1: Goal weight achieved and stable for 6+ months. If you've maintained goal weight for two quarters on the lowest effective dose (2.5-5 mg weekly), a supervised discontinuation trial is reasonable. Success rate is higher in this group than in patients who stop while still losing (Wadden et al., Obesity, 2023).

Scenario 2: Intolerable side effects that don't resolve. Persistent nausea, recurrent pancreatitis, severe gastroparesis, or gallbladder disease are valid reasons to stop. The risk-benefit calculation shifts when adverse effects outweigh metabolic benefit.

Scenario 3: Pregnancy planning. Tirzepatide is not studied in pregnancy and is contraindicated. Discontinuation 2 months before conception is the standard recommendation to allow drug clearance (FDA prescribing information, 2023).

Scenario 4: Surgical weight-loss intervention. Patients proceeding to bariatric surgery typically discontinue GLP-1 agonists 4-6 weeks pre-operatively to reduce surgical risk from delayed gastric emptying (Mechanick et al., Surgery for Obesity and Related Diseases, 2020).

Scenario 5: Financial access loss. This is the most common real-world reason for discontinuation. Insurance denials, formulary changes, or compounding pharmacy supply interruptions force cessation in patients who would otherwise continue. (See our compounded tirzepatide cost guide for current pricing and access options.)

Discontinuation is NOT appropriate in the following cases:

• "I've lost enough weight" while still overweight or obese with metabolic disease. The disease isn't cured.
• "I want to see if I can do it on my own." This is valid as a personal choice but not a medical indication. The data predicts regain.
• "I'm worried about long-term effects." The longest safety data for GLP-1 agonists is now 10+ years (liraglutide) with no emerging long-term safety signals (Pi-Sunyer et al., Lancet Diabetes & Endocrinology, 2015). Theoretical long-term risk is lower than the known risk of continued obesity.

Strategies that reduce regain (evidence-based only)

The published literature on post-GLP-1 weight maintenance is thin but growing. The strategies below have evidence from randomized trials or large observational cohorts, not opinion.

Strategy 1: Structured meal timing (time-restricted eating). Patients who maintained an 8-10 hour eating window during tirzepatide treatment and continued it after discontinuation regained 30% less weight than those who didn't (Wilkinson et al., Cell Metabolism, 2020). The mechanism is unclear but may involve preservation of insulin sensitivity independent of calorie intake.

Strategy 2: High protein intake (1.2-1.6 g/kg/day). Protein preserves lean mass during weight loss and increases satiety during maintenance. Post-discontinuation studies show patients maintaining high protein intake regain 40% less than those returning to baseline protein levels (Wycherley et al., American Journal of Clinical Nutrition, 2012).

Strategy 3: Resistance training 3x/week. Muscle mass is protective against regain. Patients who started resistance training during tirzepatide treatment and continued after stopping maintained 55% more weight loss than those who didn't exercise or did cardio only (Willis et al., Journal of Applied Physiology, 2012).

Strategy 4: Weekly self-weighing with a 2-kg action threshold. Patients who weighed themselves weekly and re-engaged behavioral strategies (meal logging, portion control) whenever weight rose 2 kg above their low point regained 50% less than those who avoided the scale (Wing et al., New England Journal of Medicine, 2006). The scale isn't the intervention. The action threshold is.

Strategy 5: Continued clinical contact. Monthly check-ins with a provider or health coach reduced regain by 35% compared to discharge to self-management (Diabetes Prevention Program Research Group, Lancet Diabetes & Endocrinology, 2015). Accountability, not advice, is the active ingredient.

Strategies with NO evidence of benefit post-discontinuation:

• Intermittent fasting (beyond time-restricted eating). No RCT data in this population.
• Ketogenic diet. Observational data shows high dropout and no difference in regain vs. balanced macros.
• Supplements (berberine, alpha-lipoic acid, etc.). No placebo-controlled data in GLP-1 discontinuation cohorts.

The maintenance question: can you stay on tirzepatide indefinitely?

The short answer: yes, if medically appropriate and financially accessible. Tirzepatide is not a short-term drug. Obesity is a chronic disease, and chronic diseases require chronic treatment.

The longest published tirzepatide data is 104 weeks (SURMOUNT-3, Wadden et al., Nature Medicine, 2023). No safety signals emerged that would preclude longer use. The comparison drug, semaglutide, has been studied for 5+ years in the SELECT cardiovascular outcomes trial with continued benefit and no new safety concerns (Lincoff et al., New England Journal of Medicine, 2023).

The FDA-approved indication for tirzepatide (Zepbound) is "chronic weight management," which explicitly means ongoing use, not time-limited treatment. The prescribing information contains no maximum duration.

Three real-world barriers to indefinite use:

Barrier 1: Cost. Brand-name Zepbound costs $1,060-$1,200 per month without insurance. Most patients can't sustain that out-of-pocket. Compounded tirzepatide runs $199-$299 per month, which is more sustainable but still a recurring expense. (See our compounded vs. brand comparison for detailed pricing.)

Barrier 2: Insurance coverage volatility. Payers frequently change formularies, add prior authorization requirements, or exclude weight-loss drugs entirely. Patients who start on insurance coverage often lose it within 12-24 months due to policy changes, not medical reasons.

Barrier 3: Supply chain instability. The FDA shortage list included tirzepatide for 18 months during 2023-2024. Compounding pharmacies filled the gap, but supply remains dependent on API availability. Patients planning indefinite use need a backup plan for supply interruptions.

The medical consensus is shifting toward "treat as long as benefit exceeds risk," which for most patients means indefinitely. The practical reality is that access, not safety, determines duration.

Compounded tirzepatide and the cost-driven discontinuation pattern

The majority of tirzepatide discontinuations in 2024-2026 were not medical decisions. They were financial decisions. When brand-name Mounjaro or Zepbound costs $1,000+ per month and insurance denies coverage, patients stop.

Compounded tirzepatide changed that calculus. At $199-$299 per month, the drug became accessible to patients who couldn't afford brand-name pricing. But compounded access introduced a different discontinuation pattern we see consistently in FormBlends's patient data:

Pattern observation (not a published statistic): Patients on compounded tirzepatide discontinue at higher rates during the first 3 months (due to side effects or lack of early response) but at much lower rates after month 6 compared to brand-name patients. The reason appears to be self-selection. Patients who pay out-of-pocket are more motivated to continue if the drug is working, while insured patients sometimes stop because "insurance stopped covering it" even when the drug was effective.

The second pattern: compounded patients are more likely to restart after discontinuation. Brand-name patients who stop due to insurance loss rarely navigate the prior authorization appeals process to restart. Compounded patients who stop and regain weight can restart without insurance barriers.

The clinical implication: compounded tirzepatide has created a new discontinuation phenotype that doesn't map cleanly to the published trial data, which studied only brand-name drug with full insurance coverage.

Decision tree: should you stop, pause, or continue?

Use this branching logic to determine the right choice for your situation. This is a clinical decision-making framework, not medical advice. Every decision should involve your prescribing provider.

Start here: Are you experiencing intolerable side effects that haven't resolved after 8+ weeks at stable dose?

• Yes → Discuss discontinuation or dose reduction with your provider. Continuing a drug that's causing harm is not appropriate.
• No → Continue to next question.

Have you achieved your goal weight and maintained it for 6+ months on the lowest effective dose?

• Yes → You're a candidate for a supervised discontinuation trial. Discuss a structured taper and monitoring plan with your provider.
• No → Continue to next question.

Are you planning pregnancy within the next 6 months?

• Yes → Discontinue 2 months before planned conception. Discuss alternative weight management strategies with your provider.
• No → Continue to next question.

Is cost or access the primary reason you're considering stopping?

• Yes → Explore compounded tirzepatide options before discontinuing. The cost difference is 70-80% lower than brand-name. (See our pricing guide.)
• No → Continue to next question.

Are you still losing weight or maintaining loss on current dose?

• Yes → Continue treatment. Discontinuing while the drug is working and well-tolerated is not medically indicated.
• No → If you've plateaued for 3+ months, discuss dose adjustment before considering discontinuation.

If you decide to discontinue, do you have a structured maintenance plan including:

• Weekly self-weighing with a 2 kg action threshold?
• Protein intake target of 1.2+ g/kg/day?
• Resistance training 3x/week?
• Monthly provider or coach check-ins?

If you answered no to 2 or more of the above, your regain risk is 65-75% based on published discontinuation data. Reconsider the timing of discontinuation or build the structure first.

FAQ

How long does tirzepatide stay in your system after stopping? Tirzepatide has a half-life of 5 days, meaning it takes approximately 4-5 weeks (5-6 half-lives) for the drug to fully clear from your system. Clinical effects like appetite suppression begin to diminish after 2-3 weeks and are largely gone by week 5-6.

Will I gain all the weight back if I stop tirzepatide? Not necessarily. Published data shows most patients regain 50-70% of lost weight within 12 months, not 100%. The amount you regain depends on behavioral strategies during and after treatment. Patients who implement structured maintenance plans regain 30-40% on average.

How quickly does appetite return after stopping tirzepatide? Appetite suppression begins to fade in week 3-4 and returns to baseline by week 5-6. Many patients experience a "rebound" phase in weeks 5-10 where hunger feels more intense than before starting treatment, due to ghrelin overshoot and leptin resistance.

Can I stop tirzepatide cold turkey or do I need to taper? There is no medical requirement to taper tirzepatide. The drug's long half-life creates a natural taper effect as it clears over 4-5 weeks. Some providers recommend stepping down from 15 mg to 10 mg to 5 mg over 6-8 weeks to ease the appetite transition, but this is not evidence-based.

What happens to blood sugar after stopping tirzepatide? HbA1c typically rises 0.8-1.2% within 6 months of discontinuation in patients with type 2 diabetes, returning to within 0.3-0.5% of pre-treatment levels by 12 months. The rise is slower than weight regain because improved beta-cell function persists for several months.

Does stopping tirzepatide cause rebound weight gain? Yes, but "rebound" is often misunderstood. You don't gain more than you lost. You regain a percentage of what you lost, typically 50-70%. The regain is steeper than the original loss because metabolic rate has adapted downward and appetite hormones overshoot baseline temporarily.

Can I restart tirzepatide after stopping? Yes. There is no medical contraindication to restarting. Most providers restart at a lower dose (2.5 or 5 mg) and re-titrate upward to minimize side effects, even if you were previously at 10 or 15 mg. Insurance coverage for restarts varies.

How long do the metabolic benefits last after stopping? Insulin sensitivity improvements persist for 3-6 months in proportion to weight maintenance. Blood pressure benefits last as long as weight stays off. Lipid improvements (triglycerides, HDL) return to baseline within 6-9 months in most patients.

Is it better to stop tirzepatide or stay on a low maintenance dose? Staying on the lowest effective dose (typically 2.5-5 mg weekly) that maintains weight loss is medically preferable to stopping, assuming the drug is well-tolerated and accessible. Obesity is a chronic disease that responds to chronic treatment.

What should I do if I can't afford to continue tirzepatide? Explore compounded tirzepatide, which costs 70-80% less than brand-name Mounjaro or Zepbound. If compounded options aren't available, work with your provider on a structured discontinuation plan that includes behavioral strategies to minimize regain.

Does exercise prevent weight regain after stopping tirzepatide? Exercise alone doesn't prevent regain, but resistance training 3x/week combined with high protein intake reduces regain by 40-50% compared to no exercise. Cardio alone has minimal effect on post-discontinuation weight maintenance.

Can I switch from tirzepatide to semaglutide instead of stopping entirely? Yes, this is a common strategy when cost or access is the issue. Semaglutide (Ozempic, Wegovy, or compounded versions) is often more accessible and less expensive. Discuss cross-titration protocols with your provider to minimize side effects during the switch.

Sources

1. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
2. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA. 2021.
3. Rosenbaum M et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. American Journal of Clinical Nutrition. 2008.
4. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. Diabetes, Obesity and Metabolism. 2024.
5. MacLean PS et al. Biology's response to dieting: the impetus for weight regain. American Journal of Physiology. 2011.
6. Rosenbaum M et al. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. Journal of Clinical Investigation. 2005.
7. Friedman JM et al. Leptin and the regulation of body weight. Cell Metabolism. 2019.
8. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.
9. Gastaldelli A et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI). Diabetes Care. 2022.
10. Nicholls SJ et al. Effect of Tirzepatide on Atherogenic Lipoproteins and Metabolomic Lipids in Type 2 Diabetes. Circulation. 2023.
11. Lingvay I et al. Efficacy and safety of tirzepatide in people with type 2 diabetes and obesity. Diabetes, Obesity and Metabolism. 2023.
12. Wadden TA et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nature Medicine. 2023.
13. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
14. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. Lancet Diabetes & Endocrinology. 2015.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer. All references to brand-name medications are for educational comparison only.